Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11377)	2/27/2018 3:01:57 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

>> Another good call by Alfredo Fontanini << Returning to this subject. Alfredo has been providing objective guidelines toward what might constitute success for mrns, pointing to robust sage results and a mrns report that p values will not be given for expected results. That is, he's giving objective guidance which might favor sage, many observers. Major rationale is a difference in bioavailability? MCs (subtracting cash from sage MC), sage:mrns = 35 A majority of call bets (today's volume and open interest) are placed for 3/15, rather than for 4/20. $5 strike March puts are currently $0.70 with the share price at 5.26, but the same strike will cost you $1.50 (ouch!) for April. And a majority of put open interest and today's volume goes to April. So........ do we have any reason to believe that the data will be released before 3/15?? Anyone know?